---
anonymous_label: OUT-44
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: d95ab22c7993f08945b0f6a7e52a9f3810e29c6dccf40203e81d2d0a8318aa36
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-44

### Recommendation: Run the Claim File Review

I recommend you commit to the **Claim File Review**.

#### Reasoning
You are currently facing a classic "false positive" signal. Your lagging indicators (bookings, renewals) look strong, but your leading indicators (user behavior, qualitative feedback) are flashing red.

The expansion bookings are likely a result of **sales engineering** (bundle pricing and roadmap promises) rather than **product value**. The usage spike is a "mirage" caused by managers auditing the tool rather than adjusters using it to do their jobs. Most critically, you have a "black box" problem: in regulated segments, the tool is unusable because it lacks explainability.

Here is why the other options fail:
*   **Scale DraftPath Broadly:** This is reckless. You are seeing signs of "novelty churn" (high initial use, then drop-off). Scaling a leaky bucket only accelerates churn.
*   **Usage Quality Sprint:** This measures *quantity* of behavior, not *quality* of outcome. You already know the return rates are low for adjusters; knowing exactly how low they are doesn't tell you *why* they aren't returning.
*   **Commercial Cleanroom:** This is too late and too risky. With the budget locking in 12 days, you don't have time to run a controlled experiment on renewal cycles. Furthermore, it tests the *price*, not the *product*.
*   **Narrow to Health-Liability:** This is a premature pivot. You know health-liability has an explainability problem, but you don't yet know if the core logic of DraftPath is flawed across all segments or just missing a specific feature (transparency/citations).

The **Claim File Review** is the only option that attacks the root cause: the gap between a "proposed action" and an "executed action." By auditing actual files, you will discover if adjusters are overriding the tool because it's wrong, or simply because they don't trust a suggestion they can't explain. This provides the "ground truth" needed to decide if DraftPath needs a pivot, a feature addition (explainability), or a total rewrite.

#### The Strongest Reason Against It
The Claim File Review is **slow and manually intensive**. Unlike the Usage Quality Sprint, it doesn't provide a real-time dashboard for the board. It relies on a small sample size, which may lead to "anecdotal bias" where the struggles of a few vocal adjusters outweigh the silent success of others. It provides no immediate "commercial" win to justify the budget in the eyes of a Sales-driven executive team.

#### Evidence That Would Change My Mind
I would pivot to the **Usage Quality Sprint** if you discover that the "drop-off" after two days is not due to product failure, but due to a **lack of permissions or technical friction** (e.g., the tool is slow, or adjusters lack the SSO rights to access it daily).

If the data shows that users *want* to return but are blocked by a technical hurdle rather than a value deficit, the problem is an operational one (trackable via event tracking) rather than a strategic one (requiring file review).
